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Pages with reference to book, From 14 To 15 
Ikram A. Burney, Imtiaz A. Malik ( Department of Medieine, The Aga Khan University Hospital, Karachi. ) 
Modern chemotherapy and radiation treatment of Hodgkin’s disease has resulted in overall cure rates in
excess of 60%1. However, the greatly improved survival rates have also led to increasing incidence of
long-term side-effects of these treatment modalities2. The most serious consequence is the occurrence
of second cancer3. We report a case of non-Hodgkin’s lymphoma occurring in a patient who was
previously treated for Hodgkin’s disease.
Case Report 
A 70 year old male presented with three months history of bilateral enlargement of cervical and
supraclavicular lymph nodes. Excision biopsy of supraclavicular node revealed Hodgkin’s disease,
mixed cellularity type. Chest x-ray showed involvement of bronchopulmonary and perihilar nodes and
CT scan of the abdomen revealed splenic enlargement and para-aortic lymphadenopathy. The patient
was staged to have IIIA disease.He was started on the COPP/ABV hybrid regimen and received four
cycles of chemotherapy. At the end of therapy, he was incomplete clinical and radiological remission
except for the chest x-ray, which showed hazines of left hemithorax suggestive of diffuse pneumonic
changes. Bronchoalveolar lavage revealed the presence of pseudomonas aeruginosa and acid fast
bacilli. The patient was treated with appropriate antibiotics and was also started on anti-tuberculous
therapy. He remained well in the following year, after which he was again found to have cervical
lyniphadenopathy. A fine needle aspiration biopsy revealed features suggestive of non-Hodgkin’s
lymphoma. An excision biopsy confirmed the presence of mixed small and large diffuse non-Hodgkin’s
lymphoma (Intermediate grade according to the International Working Formulation). The patient was
subsequently found to have stage IIA disease and was started on the CHOP regimen.
Discussion 
Secondary cancers are important long term complications of the treatment of Hodgkin’s disease2,3.
Various types of secondaiy malignancies have been reported to occur. These include acute non-
lymphocytic leukemia (ANLL), nonHodgkin’s lymphoma (NHL) and solid tumours e.g., melanoma,
breast, lung, thyroid and gastric cancer4-6. The overall risk continues to increase with the passage of
time and is around 10% after 10 years of observation following the treatment of Hodgkin’s disease. The
risk is higher in ounger patients6.7. Secondary ANLL is widely thought to be due to the use of
alkylating agents and procarbazine8,9. Secondary solid tumours are generally regarded to occur
following radiotherapy10,11
The increased risk of developing NHL could be attributed to either chemo or radiotherapy oras a part of
the natural history of Hodgkin’s disease4,5,6,11. In one study, the actuarial risk of developing NHL was
found to be 0.5% at 10 years and 1.6% 15 years after the successful treatment of Hodgkin’s disease5.
The risk was higher in patients who received a combination of chemo and radiotherapy as compared to
those who were treated with either of the two The proposed mechanisms are either direct mutagenic
effect of these two modalities orby activation of some latent oncogenic viruses. Alternatively, excessive
occurrence of NHL in such patients has been ascribed to the immunocompromised status of the
host4,6,13.
Our patient responded well to the initial chemotherapy and was clearly documented to be in complete
clinical and radiological remission at the end of the fourth cycle. However, at the same time, he was
found to have pulmonary tuberculosis and could not continue his chemotherapy to a total number of six
cycles. During the full-length course of treatment fom tuberculosis, the patient remained in complete
remission. The lymph nodes reappeared 15 months after the initial diagnosis of Hodgkin’s disease, at
which stage the diagnosis of NHL was made. To rule out the possibility of the disease being NHL all
along, the histopathology slides were reviewed retsospectively by two pathologists. There was no
suggestion of the existence of NHL in the specimen. Also, there was no evidence of Hodgkin’s disease
in the later specimen.
The question whether the drugs are implicated in the etiogenesis of NHL in this patient, or if it was the
severely immunocompromised status of the host which led to the second cancer, cannot be answered.
The patient received four cycles of cyclophosphamide. procarbazine and etoposide, all of whom have
been known to be associated with the development of second cancers. On the other hand, the patient
seemed to be immunocompromised, as suggested by the occurrence of various infections.
immunosuppression is usually present at the time of the diagnosis of Hodgkin’s disease and is known to
persist long after the treatment is completed. Immunosuppression may lead to the clonal proliferation
of B cells14. Although no uniform immunologic pattern of the secondary NHL has been documented in
the literature, the muajority seem to be of B cell origin12. Our patient had diffuse mixed small and large
type (intermediate graae) ot NHL which is usually of the B cell origin. Immunohistochemical studies
were not done in this case. The relative risk of the occurrence of the second cancer decreases with the
increasing age and was found to be 1.0% in patients older than 60 years of age.
The secondary NJHL is treated ill a similar wa as the de novo tumour. Response rates to the
combination chemotherapy of more than 55% have been described in the literature5.
This case signifies the importance of repeat biopsy in patients with apparent relapse of Hodgkin’s
disease, as the diagnosis of a second cancer has both therapeutic and prognostic implications.
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